BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 27013402)

  • 1. A Modified Model for Assessment for Retreatment with Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients.
    Chen L; Ni CF; Chen SX; Cao JM; Zhu HD; Guo JH; Zhu GY; Zhong BY; Ding W; He SC; Deng G; Teng GJ
    J Vasc Interv Radiol; 2016 Sep; 27(9):1288-1297. PubMed ID: 27013402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma.
    Kloeckner R; Pitton MB; Dueber C; Schmidtmann I; Galle PR; Koch S; Wörns MA; Weinmann A
    J Vasc Interv Radiol; 2017 Jan; 28(1):94-102. PubMed ID: 27562621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
    Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z
    J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
    Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT
    Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.
    Ni JY; Sun HL; Chen YT; Luo JH; Chen D; Jiang XY; Xu LF
    World J Gastroenterol; 2014 Dec; 20(46):17483-90. PubMed ID: 25516662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization.
    Adhoute X; Pénaranda G; Raoul JL; Bollon E; Pol B; Letreut YP; Perrier H; Bayle O; Monnet O; Beaurain P; Muller C; Hardwigsen J; Lefolgoc G; Castellani P; Bronowicki JP; Bourlière M
    Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):706-715. PubMed ID: 28195873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization.
    Zhou DS; Xu L; Luo YL; He FY; Huang JT; Zhang YJ; Chen MS
    World J Gastroenterol; 2015 May; 21(18):5582-90. PubMed ID: 25987783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
    Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
    J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Azemoto R; Shinozaki M; Yoshikawa M; Yokosuka O
    PLoS One; 2015; 10(4):e0125244. PubMed ID: 25919025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma.
    Hickey R; Mouli S; Kulik L; Desai K; Thornburg B; Ganger D; Baker T; Abecassis M; Ralph Kallini J; Gabr A; Gates VL; Benson Iii AB; Lewandowski RJ; Salem R
    J Vasc Interv Radiol; 2016 Jun; 27(6):795-802. PubMed ID: 27038686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of hepatic resection and transarterial chemoembolization for solitary hepatocellular carcinoma.
    Zhang DZ; Wei XD; Wang XP
    World J Gastroenterol; 2015 Apr; 21(15):4635-43. PubMed ID: 25914473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma.
    Sieghart W; Hucke F; Pinter M; Graziadei I; Vogel W; Müller C; Heinzl H; Trauner M; Peck-Radosavljevic M
    Hepatology; 2013 Jun; 57(6):2261-73. PubMed ID: 23316013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C.
    Li L; Gou CY; Li JY; Achakzai R; Li XH
    Hepatobiliary Pancreat Dis Int; 2016 Apr; 15(2):152-7. PubMed ID: 27020631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival.
    Mouli SK; Hickey R; Thornburg B; Sato KT; Desai K; Gabr A; Kallini JR; Niemeri H; Kircher S; Mulcahy MF; Benson Iii AB; Gupta R; Salem R; Lewandowski RJ
    J Vasc Interv Radiol; 2016 Sep; 27(9):1279-1287. PubMed ID: 27062355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
    Biolato M; Gallusi G; Iavarone M; Cabibbo G; Racco S; De Santis A; Corte CD; Maida M; Attili AF; Sangiovanni A; Cammà C; La Torre G; Gasbarrini A; Grieco A
    Ann Hepatol; 2018; 17(1):110-118. PubMed ID: 29311396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the Interval between Transarterial Chemoembolization Sessions on Survival in Patients with Unresectable Hepatocellular Carcinoma.
    Kim HD; An J; Kim JH; Gwon DI; Shin JH; Ko GY; Yoon HK; Sung KB; Kim KM; Lee HC
    J Vasc Interv Radiol; 2016 Apr; 27(4):504-13. PubMed ID: 26896049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ART score is not effective to select patients for transarterial chemoembolization retreatment in an Italian series.
    Terzi E; Terenzi L; Venerandi L; Croci L; Renzulli M; Mosconi C; Allegretti G; Granito A; Golfieri R; Bolondi L; Piscaglia F
    Dig Dis; 2014; 32(6):711-6. PubMed ID: 25376288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with portal vein invasion: safety, efficacy, and prognostic factors.
    Chern MC; Chuang VP; Liang CT; Lin ZH; Kuo TM
    J Vasc Interv Radiol; 2014 Jan; 25(1):32-40. PubMed ID: 24290099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
    Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
    J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.